Concomitant epidermal growth factor receptor mutation/c-ros oncogene 1 rearrangement in non-small cell lung cancer: A case report

Figure 1 Histological and immunohistochemical features. A: Histology of lung biopsy; B: Expression pattern of thyroid transcription factor 1.

Figure 2 Detection of epidermal growth factor receptor mutation and c-ros oncogene 1 rearrangement using high sensitivity next-generation sequencing. A: Epidermal growth factor receptor L858R mutation; B: EZR-ROS1 E10R34 fusion.

Figure 3 Serial computed tomography images. A: Computed tomography (CT) after postoperative recurrence; B: CT after 1 month of gefitinib therapy. Progressive disease of the lung was detected; C: CT after 53 months of crizotinib therapy. Stable disease was detected.